Swiss cancer giant Roche (ROG: SIX) has presented an exploratory analysis from the Phase III IMvigor010 study of checkpoint blocker Tecentriq (atezolizumab) in muscle-invasive urothelial cancer (MIUC).
The firm presented the results at the virtual annual congress of the European Society for Medical Oncology Immuno-Oncology.
The trial, which compared the therapy with observation, is testing Tecentriq as a post-surgical monotherapy treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze